Document:

EX-10.1

 Exhibit 10.1 
  

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 1

 CONFIDENTIAL 

FIRST AMENDMENT TO LEASE 

This First Amendment to Lease (“First Amendment”) is made as of September 16, 2013, by and between ARE-MA REGION NO.
48, LLC, a Delaware limited liability company (“Landlord”), and ARIAD PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). 

RECITALS 
 A.
Landlord and Tenant have entered into that certain Lease Agreement dated as of January 4, 2013 (the “Lease”), wherein Landlord leased to Tenant certain premises (“Original Premises”; with the Expansion Space
and New Atrium Area, as defined below, the “Premises”) located at 75-125 Binney Street, Cambridge, Massachusetts more particularly described in the Lease. 

B. Tenant desires to expand the Original Premises demised under the Lease by adding (1) approximately 135,988 rentable square feet
(“Expansion Space”) on the non-retail portion of Floor L1 and the entirety of Floors L2 through L4 (inclusive of 3,500 RSF on the mezzanine) in the 75 Binney Building, and (2) approximately 6,000 rentable square feet in a new
atrium area (“New Atrium Area”) to be constructed between the 125 Binney Building and the 75 Binney Building, and Landlord is willing to lease such portions of the Project to Tenant on the terms herein set forth. 

C. Landlord and Tenant desire to amend the Lease to add the Expansion Space and the New Atrium Area to the Original Premises, to provide for
the improvement of the Expansion Space and the New Atrium Area, to confirm their agreement as to the rentable square footage of the Premises, and to address other matters more particularly set forth below. 

D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Lease. 

AGREEMENT 
 Now,
therefore, the parties hereto agree that the Lease is amended as follows: 
 1. Premises; Measurements; Square Footage and Expense
Computation Chart; Security Deposit. 
 (a) Premises. Upon full execution hereof by Landlord and Tenant, the term
“Premises” as set forth in the Basic Lease Provisions is hereby amended by deleting the text thereof, substituting therefor the following: 

“Premises: That portion of the Project, containing approximately 386,111 rentable square feet, as shown on Exhibit A, and as listed
below: 
  

							
	 75 Binney Building:
	  	 Floor L1:
	  	 	15,368	  
		  	 L1 Mezzanine:
	  	 	3,500	  
		  	 Floor L2:
	  	 	38,984	  
		  	 Floor L3:
	  	 	39,131	  
		  	 Floor L4:
	  	 	39,006	  
		  	 Floor L5 and its connecting bridge:
	  	 	27,197	  
			
	 125 Binney:
	  	 Floor L1:
	  	 	32,047	  
		  	 L1 Mezzanine:
	  	 	3,449	  
		  	 Floor L2:
	  	 	47,820	  
		  	 Floor L3:
	  	 	47,692	  
		  	 Floor L4:
	  	 	47,982	  
		  	 Floor L5:
	  	 	37,936	  
			
	 New Atrium Area
	  	 New Atrium Area:
	  	 	6,000	  

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 2

 CONFIDENTIAL 

 

 (b) Description of Premises. Exhibit A to the Lease is hereby deleted
and Exhibit A attached hereto is hereby substituted therefor. 
 (c) Measurements. Exhibit A-1 of the
Lease is hereby deleted. The parties agree that the Premises will not be re-measured, and that the rentable square footages set forth herein shall be final and binding upon the parties. 

(d) Square Footage; Expense Computation. The Square Footage and Expense Computation Chart set forth in the Basic Lease Provisions is
hereby deleted, and the attached Exhibit B-1 is substituted therefor. 
 (e) Garage. Section 1 of the Lease is
hereby amended by deleting the last 2 sentences thereof. 
 (f) Tenant’s Share. Section 5(f) of the Lease is amended by
deleting the text thereof and substituting therefor the following: 
 “(f) Tenant’s Share. “Tenant’s Share” shall be
the percentage set forth in the Basic Lease Provisions as Tenant’s Share. Landlord may equitably increase Tenant’s Share for an item of expense or cost reimbursable by Tenant that relates to a repair, replacement, or service that benefits
only the Premises or only a portion of the Project that includes the Premises or that varies with occupancy or use. Base Rent, Tenant’s Share of Operating Expenses, and all other amounts payable by Tenant to Landlord hereunder are collectively
referred to herein as “Rent”. 
 (g) Security Deposit. The term “Security Deposit” is hereby amended
by deleting therefrom “11,610,490.00” and substituting therefor “$9,181,719.50”. Section 6(c) of the Lease is hereby deleted. 

2. Commencement Date. 

(a) Section 2(b) of the Lease is hereby amended by replacing the word “Premises” in each of clauses (i), (ii) and
(iii) of the first sentence thereof with the words “Original Premises and New Atrium Area”, it being agreed that the Commencement Date for the Expansion Premises shall be deemed to occur on the Commencement Date for the Original
Premises and New Atrium Area as defined therein. 
 (b) The parties acknowledge that the schedule for improvement of the Expansion Premises
is not yet determined, and that the same shall be addressed as a Change to the Tenant Improvements in accordance with the Work Letter (subject to the payment therefor to 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 3

 CONFIDENTIAL 

 

 
the extent of available Base TI Allowance and Additional TI Allowance as set forth in the Work Letter (as amended by Section 4 below) and Exhibit G of the Lease).
Landlord agrees to work cooperatively with Tenant to perform Tenant Improvements in the Expansion Premises on a mutually agreed upon schedule, provided that the Commencement Date shall not be affected thereby. 

3. Construction of New Atrium Area. Landlord shall design and construct the New Atrium Area in accordance with the provisions of
the First Amendment to Work Letter attached hereto as Exhibit C-1, including the thermal design criteria for the New Atrium Area (“Atrium Thermal Criteria”) which is made a part of the First Amendment to Work Letter as
Attachment 1. 
 4. TI Allowances for Expansion Space. 

(a) Landlord shall provide a Base TI Allowance of $ [***] per rentable square foot of the Expansion Space, and an Additional TI Allowance of
$[***] per rentable square foot of the Expansion Space, to be used and disbursed for the improvement of the Expansion Space in accordance with the provisions of Section 6 of the Work Letter incorporated as Exhibit C of the
Lease (except as hereinafter provided), and in accordance with the provisions of Exhibit G of the Lease. In no event shall either the Base TI Allowance for the Expansion Space, or the Additional TI Allowance for the Expansion Space, be
used for the cost of demolition of any portion of the Premises previously improved using the Base TI Allowance or the Additional TI Allowance for the space initially demised under the Lease. 

(b) Notwithstanding the provisions of Section 6.3 of the Work Letter, Tenant may have up to the fifth anniversary of the
Commencement Date (rather than the third anniversary of the Commencement Date) to requisition any unused Base TI Allowance and, subject to the provisions of clause (c) below, any Additional TI Allowance (“Expansion Space Additional TI
Allowance”), for Alterations to the Expansion Space (up to a maximum expenditure in the Expansion Space of $[***] per rentable square foot of Base TI Allowance) as to which Tenant shall have so elected by notice to Landlord delivered on or
before the Commencement Date. There shall be no TI Allowances for the New Atrium Area. 
 (c) Notwithstanding the provisions of
Section 4(b) of the Lease and Section 6.3 of the Work Letter, any Expansion Space Additional TI Allowance which may be requisitioned by Tenant for Alterations to the Expansion Space between the Commencement Date and the fifth
anniversary thereof: (a) must be the subject of up to 2 requisitions (provided that Tenant may make only 1 such requisition unless Tenant has submitted a first requisition of at least 33% of the Additional TI Allowance within 3 years after the
Commencement Date), submitted to Landlord upon completion of the Alterations to be funded thereby; and (b) Base Rent shall be increased from and after the first day of the month after the month in which each such requisition is funded, in an
amount necessary to amortize the Expansion Space Additional TI Allowance which is the subject of the requisition over the then remaining initial Term of the Lease at an interest rate of 8% per annum. 

5. Rent for Expansion Space and New Atrium Area. From and after the Commencement Date, Base Rent, Administration Rent, and
Additional Rent shall be payable with respect to the Expansion Space and the New Atrium Area in accordance with the terms of the Lease. Notwithstanding the foregoing: (a) Base Rent and Administration Rent payable in accordance with the Basic
Lease Provisions and the provisions of Section 3 and Section 4 of 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 4

 CONFIDENTIAL 

 

 
the Lease shall be waived with respect to the Expansion Space for the 15-month period from and after the Commencement Date; and (b) Tenant’s Share of Operating Expenses for the
Expansion Space payable in accordance with Section 5 of the Lease shall be waived until the earlier to occur of: (i) the expiration of the 24-month period from and after the Commencement Date; or (ii) the date upon which Tenant
or any approved subtenant occupies all or a portion of the Expansion Premises for the Permitted Uses (pro rated for such portion of the Expansion Premises as is occupied by Tenant or such subtenant). 

6. Security Deposit. The $5,805,245.00 Security Deposit presently required under the provisions of Section 6 of the
Lease is hereby increased to $9,181,719.50 (reflecting the 135,988 rentable square feet included in the Expansion Space and the 6,000 rentable square feet included in the New Atrium Area, at the rate of $23.78 per rentable square foot). Tenant shall
deliver to Landlord a replacement Letter of Credit for the Security Deposit in the amount of $9,181,719.50 within 30 days after the date of this First Amendment to Lease. The Security Deposit, as so increased, shall be subject to elimination in
accordance with the provisions of Section 6(d) of the Lease, upon satisfaction of the Elimination Requirements set forth therein. 

7. Use. Section 7 of the Lease is hereby amended by adding the following clause (f) thereto: 

“(f) The parties acknowledge that the approval of the New Atrium Area by the City of Cambridge Planning Board (“City Approval”)
contains the requirement that the New Atrium Area include features promoting and supporting public access thereto, possibly including a café, indoor seating, and/or restrooms. Tenant shall have the right to control any use of the New Atrium
Area as part of its Premises, including retail sales or services to be provided in or about the New Atrium Area pursuant to the City Approval, provided that Tenant shall be responsible for making such arrangements, whether by sublease, license or
other operating agreement reasonably approved by Landlord, which comply with the requirements of the City Approval for such public access features and facilities.” 

8. Parking. Tenant’s Pro Rata Share of Parking Spaces under the provisions of Section 10 of the Lease is hereby
increased from [***] parking spaces to [***] parking spaces, based upon the Current Cambridge Parking Ratio of [***] parking spaces per [***] square feet of “gross floor area” included in the Original Premises, and the additional
“gross floor area” included in the Expansion Premises and New Atrium Area. Notwithstanding any provision of the Lease to the contrary, during the 24-month period following the Commencement Date, Tenant may elect by written notice to
Landlord not to use all or a portion of the [***] additional parking spaces associated with the Expansion Space, and, in such event, Tenant shall not be obligated to pay the monthly parking charge for such parking spaces during that period. 

9. Excess Rent With Respect to Assignment or Subletting of Expansion Space. Notwithstanding the provisions of
Section 22(d) of the Lease, the requirement that Tenant pay to Landlord Excess Rent with respect to any assignment or subletting of the Expansion Space shall be waived for the period from the Commencement Date through the fifth
anniversary thereof, it being agreed that Tenant shall be entitled to retain all Excess Rent with respect to the Expansion Space during that period. 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 5

 CONFIDENTIAL 

 

 10. Signage. Section 38 of the Lease is hereby amended by adding
the following clauses (c) and (d) thereto: 
 “(c) In addition to the signage described in clauses (a) and
(b) above, Tenant shall have the sole and exclusive right to install additional signage on the 75 Binney Building and the 125 Binney Building as may be approved by the City of Cambridge. 

(d) Any retail signage for the retail spaces in the Project shall be subject to the mutual approval of Landlord and Tenant, which approval
shall not be unreasonably withheld, delayed or conditioned.” 
 11. Confirmation of Additional Lease Provisions Affected by First
Amendment. As a consequence of the inclusion of the Expansion Space within the Premises in accordance with this First Amendment, Landlord and Tenant hereby confirm as follows: 

(a) [***] 
 (b)
Section 3(b) (Administration Rent). Administration Rent payable under the provisions of Section 3(b) of the Lease shall be $[***] per rentable square foot in the Premises (increased on each Adjustment Date by [***]%).

 (c) Section 5(c)(Definition of Eligible Capital Items). Section 5(c) is hereby amended by adding at the end
thereof the following: 
 [***] 

(d) Section 5(e)(vii) (Operating Expense Gross Up for Multiple Tenancy of 75 Binney Building). The first sentence of
Section 5(e)(vii) is hereby deleted from the Lease. 
 (e) Sections 39 (Right of First Offer), Section 40 (Right to
Expand), and Section 42 (Right of First Refusal to Lease). Subject to the provisions of Section 8 of this First Amendment, Section 39, Section 40, and Section 42 of the Lease, and all
references thereto, are hereby deleted from the Lease, as the same are superseded by the provisions of this First Amendment. 
 12.
Confidentiality. Landlord and Tenant agree that the Lease and all negotiations and related documentation shall remain confidential and that no press or other publication, release or communication to the general public concerning the
proposed transaction contemplated herein will be issued without the other party’s prior written approval, unless (a) such disclosure is required by applicable law, or (b) such information has been publicly disclosed to date.
Notwithstanding the foregoing: Landlord or Tenant may disclose the existence and/or contents of this First Amendment to Lease: (i) as required by Legal Requirements or in response to a request by a Governmental Authority; (ii) as
necessary to (x) manage its investment in the Building or Project or (y) existing or prospective professional advisors, including, without limitation, analysts, investors, tax preparers, bank personnel, brokers, business advisors, legal
advisors, lenders, and financial advisors; (iii) as necessary to manage and enforce the terms of the Lease, (iv) if the information is already a matter of public record or generally known to the public, or (v) as otherwise reasonably
necessary in the course of operations of the property or business of Landlord or Tenant and either of their affiliates, including, without limitation, capital formation. 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 6

 CONFIDENTIAL 

 

 13. Miscellaneous. 

(a) This First Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and
contemporaneous oral and written agreements and discussions. This First Amendment may be amended only by an agreement in writing, signed by the parties hereto. 

(b) This First Amendment is binding upon and shall inure to the benefit of the parties hereto and their respective permitted successors in
interest. 
 (c) This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of
which when taken together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any
other counterpart identical thereto except having additional signature pages executed by other parties to this First Amendment attached thereto. 

(d) Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively
“Broker”) in connection with this transaction other than CB Richard Ellis-N.E. Partners LP and Cassidy Turley, and that no Broker, other than CB Richard
Ellis-N.E. Partners LP and Cassidy Turley, who shall be paid by Landlord pursuant to a separate Agreement, brought about this transaction. Landlord and Tenant each hereby agree to indemnify and hold
the other harmless from and against any claims by any Broker (other than CB Richard Ellis-N.E. Partners LP and Cassidy Turley) claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as
applicable, with regard to this leasing transaction. 
 (e) As amended and/or modified by this First Amendment, the Lease is hereby ratified
and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this First Amendment. In the event of any conflict between the provisions of this First Amendment and the provisions of the Lease, the
provisions of this First Amendment shall prevail. Whether or not specifically amended by this First Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this
First Amendment. 
 (f) Landlord and Tenant shall execute an amendment of the Notice of Lease in the form of Exhibit E hereto.

 (Signatures on Next Page) 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 7

 CONFIDENTIAL 

 

 IN WITNESS WHEREOF, the parties hereto have executed this First Amendment as of the day and
year first above written. 
  

			
	TENANT:
	
	 ARIAD PHARMACEUTICALS, INC.,

a Delaware corporation

		
	By:	 	 
	Name: 	 	 
	Title:	 	 
		 	Hereunto Duly Authorized

  

							
	LANDLORD:
	
	 ARE-MA REGION NO. 48, LLC,
 a
Delaware limited liability company

		
	By: 	 	ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, member
			
		 	By: 	 	ARE-QRS CORP., a Maryland corporation, general partner
				
		 		 	By:	 	 
		 		 	Name: 	 	 
		 		 	Its:	 	 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 8

 CONFIDENTIAL 

 

 EXHIBIT A 

Plan of Expansion Space 

and 
 Plan of
New Atrium Area 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 9

 CONFIDENTIAL 

 

 EXHIBIT B-1 

Square Footage and Expense Computation Chart 

[***] 
 Exhibit B pg. 1 of 2 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 10

 CONFIDENTIAL 

 

 [***] 

Exhibit B pg. 2 of 2 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 11

 CONFIDENTIAL 

 

 EXHIBIT C-1 

First Amendment to Work Letter 

This First Amendment to Work Letter is made and entered into this 12th day of August, 2013, by and between ARE-MA REGION NO. 48, LLC, a
Delaware limited liability company (“Landlord”), and ARIAD Pharmaceuticals, Inc., a Delaware corporation (“Tenant”), and is attached to and made a part of that certain First Amendment to Lease dated as of the date
hereof, with respect to the Work Letter incorporated as Exhibit C of a Lease Agreement (“Lease”) dated as of January 4, 2013, by and between Landlord and Tenant for certain premises at 75 Binney Street and
125 Binney Street, Cambridge, Massachusetts more particularly described therein. All capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Lease and the Work Letter. 

Landlord and Tenant hereby agree to amend the Work Letter as follows: 

1. New Atrium Area. A new Section 2.9 (Design of Atrium) of the Work Letter is hereby inserted into the Work Letter after
Section 2.8 thereof: 
 Section 2.9 Design of Atrium 

(a) Design for New Atrium Area. As part of Landlord’s Work under the Work Letter, Landlord shall design and construct the New Atrium Area in
accordance with the concept plans, matrix (“Matrix”) and related sketch plans referenced in Attachment 1 to this First Amendment (and including the “Atrium Thermal Criteria”, as defined in the Matrix) (collectively,
the “Approved Atrium Concept Plans”) (the “Atrium Work”). The final design of the Atrium Work shall be performed by Landlord in consultation with Tenant, and shall be consistent with the City Approval and the Approved Atrium
Concept Plans, as the same may be modified by mutual agreement of the parties. 
 (b) Cost of New Atrium Area. The cost of designing,
permitting, and constructing the Atrium Work (including the work necessary to achieve the Atrium Thermal Criteria) shall be borne by Landlord and Tenant in accordance with the Matrix (subjection to the provisions of Section 5(c) of the
Lease). 
 (c) Schedule. Attachment 1 to Exhibit C of the Work Letter (Project Milestone Schedule) is hereby deleted and
Attachment 2 to this First Amendment is substituted therefor. 
 2. Project Accounting. Landlord shall provide to Tenant (a) on a
quarterly basis: (i) an updated report as to certain costs of the Non-TI Project Improvements and the Tenant Improvements for the categories of expense identified in the attached
Exhibit D (collectively, “Reported Project Costs”), in the format attached hereto as Exhibit D. [***] Any Disclosed Documents so provided shall be subject to the following terms and conditions: 

 

	 	(a)	Any Disclosed Documents provided to Tenant shall be used by Tenant only for the Special Permitted Use and for no other use. Specifically, the Disclosed Documents shall be used only to prepare the financial statements to
be disclosed publicly by Tenant and shall not themselves be disclosed to third parties, unless required solely for the purpose of the preparation or audit of such financial statements (the “Preparing/Auditing Parties”). 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 12

 CONFIDENTIAL 

 

	 	(b)	Any Disclosed Documents provided to Tenant shall be considered “Confidential Information” and Tenant shall not copy, duplicate, deliver, disclose or transmit the Disclosed Documents or their content to any
third party without Landlord’s express prior written approval, except to the Preparing/Auditing Parties solely for the purpose of the preparation or audit of such financial statements. 

 

	 	(c)	To the extent that any Disclosed Document will be prepared by a third party, such Disclosed Document will be prepared in accordance with a specific scope of work and maybe subject to specific limitations regarding its
use by third parties, including Tenant. 

  

	 	(d)	Neither Landlord nor any of its affiliates, employees, agents, successors or assigns (collectively, the “Landlord Parties”), nor any third party that prepared any Disclosed Document, has made or shall be
deemed to have made any representations, statements or warranties of any kind as to (i) the accuracy or validity of the information contained in any Disclosed Document; or (ii) the condition or cost of construction of the Project in any
respect as a consequence of providing the Disclosed Documents. 

  

	 	(e)	Tenant is responsible for making its own independent assessment and investigation of the condition and cost of construction of the Project. 

 

	 	(f)	To the extent permitted under applicable law, Tenant agrees to indemnify, defend and hold the Landlord Parties harmless from and against losses, costs, damages, claims or causes of action (including, without limitation,
any actions initiated by Tenant shareholders) arising out of any use of the Disclosed Information by Tenant or the Preparing/Auditing Parties, or their respective agents, employees or representatives, including, without limitation, the Special
Permitted Use and any use in violation of paragraphs (a) and (b) above. 

  

	 	(g)	Tenant, for itself and its agents, affiliates, successors and assigns, hereby releases and forever discharges each of the Landlord Parties from any and all rights, claims and demands at law or in equity, whether direct
or indirect, known or unknown, foreseen or unforeseen, at the time of this First Amendment, which Tenant has or may have in the future, arising out of the financial information provided by Landlord in the Disclosed Documents. With respect to the
waiver and release set forth herein relating to unknown and unsuspected claims, Tenant hereby acknowledges that such waiver and release is being made after obtaining the advice of counsel and with full knowledge and understanding of the consequences
and effects of such waiver. Nothing set forth herein shall in any way waive or limit any right or obligation of Landlord or of Tenant as otherwise set forth in the Lease which either party now has or may have in the future. 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 13

 CONFIDENTIAL 

 

 3. Architect. Section 3.1 of the Work Letter is revised to substitute
“Payette Architects and Chan Mock Architects” in lieu of “Perkins + Will” as the TI Architect. 
 Except as
hereinabove amended, the Work Letter remains in force and effect in accordance with its terms. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT
BLANK] 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 14

 CONFIDENTIAL 

 

 IN WITNESS WHEREOF, Landlord and Tenant have executed this First Amendment to Work Letter to
be effective on the date first above written. 
  

							
	LANDLORD:
	
	 ARE-MA REGION NO. 48, LLC,
 a
Delaware limited liability company

		
	By: 	 	 Alexandria Real Estate Equities, L.P.,

a Delaware limited partnership, its managing member

			
		 	By: 	 	 ARE-QRS Corp.,
 a Maryland
corporation, its general partner

				
		 		 	By:	 	 
		 		 	Name: 	 	 
		 		 	Title:	 	 

  

			
	TENANT:
	
	 ARIAD PHARMACEUTICALS, INC.,
 a
Delaware corporation

		
	By:	 	 
	Name: 	 	 
	Title:	 	 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 15

 CONFIDENTIAL 

 

 ATTACHMENT 1 TO EXHIBIT C-1 

APPROVED ATRIUM CONCEPT PLANS 

See attached 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 16

 CONFIDENTIAL 

 

 ATTACHMENT 2 TO EXHIBIT C-1 

REVISED PROJECT MILESTONE SCHEDULE 

See attached 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 17

 CONFIDENTIAL 

 

 EXHIBIT D 

FORMAT FOR CERTAIN REPORTED PROJECT COSTS 

[***] 
 Exhibit D pg. 1 of 2 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 18

 CONFIDENTIAL 

 

 [***] 

Exhibit D pg. 2 of 2 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 19

 CONFIDENTIAL 

 

 EXHIBIT E 

AMENDED AND RESTATED NOTICE OF LEASE 

AMENDED AND RESTATED NOTICE OF LEASE 

Dated: September     , 2013 

Notice is hereby given, pursuant to Section 4 of Chapter 183 of the General Laws of Massachusetts, of the following amended Lease: 

 

							
	EXECUTION DATE OF LEASE:	  	As of January 4, 2013	  
		
	EXECUTION DATE OF FIRST AMENDMENT TO LEASE:	  	As of September     , 2013.	  
		
	LANDLORD:	  	ARE-MA Region No. 48, LLC, a Delaware limited liability company.	  
		
	TENANT:	  	ARIAD Pharmaceuticals, Inc., a Delaware corporation.	  
		
	PROJECT:	  	The land (“Land”) in the City of Cambridge, Middlesex County, Commonwealth of Massachusetts as described on Exhibit A hereto together with the following to be constructed by Landlord on the
Land: (i) the buildings which shall contain approximately 388,270 rentable square feet of space to be located at 75 Binney Street (the “75 Binney Building”) and 125 Binney Street (the “125 Binney
Building”), and (ii) a garage containing approximately 397 parking spaces (“Garage”), and all other improvements on the Land and all appurtenances thereto from time to time located thereon and all appurtenant and other
rights described or referred to in the Lease.	         
		
	PREMISES:	  	That portion of the Project, containing approximately 386,111 rentable square feet, as shown on Exhibit A-1, and as listed below:	   
			
		  	75 Binney Building:	  			
		  	Floor L1:	  	 	15,368	  
		  	L1 Mezzanine:	  	 	3,500	  
		  	Floor L2:	  	 	38,984	  
		  	Floor L3:	  	 	39,131	  
		  	Floor L4:	  	 	39,006	  
		  	Floor L5 and its connecting bridge:	  	 	27,197	  

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 20

 CONFIDENTIAL 

 

							
			
		  	125 Binney Building:	  			
		  	Floor L1:	  	 	32,047	  
		  	L1 Mezzanine:	  	 	3,449	  
		  	Floor L2:	  	 	47,820	  
		  	Floor L3:	  	 	47,692	  
		  	Floor L4:	  	 	47,982	  
		  	Floor L5:	  	 	37,936	  
		  	New Atrium Area:	  	 	6,000	  
		
	TERM:	  	The initial term shall commence on the Commencement Date (as defined in the Lease), and shall end one hundred eighty (180) months after the month in which the Commencement Date occurs.	    
		
	EXTENSION OPTION:	  	Tenant has the right to extend the Term for three (3) additional periods of five (5) years each pursuant to and subject to the terms and provisions in the Lease.	   
		
	GARAGE:	  	Tenant has an irrevocable license to the use of certain parking spaces in the Garage pursuant to and subject to the terms and provisions in the Lease.	   
		
	LANDLORD’S TITLE:	  	For Landlord’s title to the Project, see Quitclaim Deed dated October 25, 2012 recorded with the Middlesex South Registry of Deeds in Book 60361, Page 498.	   

 This Amended and Restated Notice of Lease is executed only for the purpose of giving notice of the existence
of the Lease and is not intended to modify, expand or reduce any of the rights of Landlord and Tenant as set forth in the Lease. All terms not otherwise defined herein shall have the meanings set forth in the Lease. 

[The balance of this page has been intentionally left blank.] 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 21

 CONFIDENTIAL 

 

 [Signature Page to Amended and Restated Notice of Lease] 

EXECUTED as a sealed instrument as of September     , 2013. 
  

															
	WITNESSES:	 		 		 		 	LANDLORD:
					
	 	 		 		 		 	ARE-MA REGION NO. 48, LLC, a Delaware limited liability company
						
	 	 		 		 		 	By:	 	Alexandria Real Estate Equities, L.P., a Delaware limited partnership, its managing member
							
		 		 		 		 		 	By:	 	ARE-QRS CORP., a Maryland corporation, general partner
								
		 		 		 		 		 		 	By:	 	 
		 		 		 		 		 		 	Name: 	 	 
		 		 		 		 		 		 	Title:	 	 

  

					
	STATE OF	  	)	  	
		  	)	  	
	COUNTY OF	  	)	  	

 On this          day of September, 2013, before me, the undersigned notary public,
personally appeared                     
                     , known personally to me, or proved to me through satisfactory evidence of identification, which was
                                          , to be
the person whose name is signed on the preceding or attached document, and acknowledged to me that he signed it voluntarily for its stated purpose, as the duly authorized signatory of the above entities, and signed the foregoing instrument for the
purposes therein contained as his/her free act and deed. 
  

	
	 
	  

	My commission expires

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 22

 CONFIDENTIAL 

 

 [Signature Page to Amended and Restated Notice of Lease] 

EXECUTED as a sealed instrument as of September     , 2013. 
  

							
	WITNESSES:	 		 	TENANT:
			
	 	 		 	ARIAD PHARMACEUTICALS, INC., a Delaware corporation
				
	 	 		 	By:	 	 
		 		 	Name: 	 	 
		 		 	Title:	 	 

  

					
	STATE OF	  	)	  	 
		  	 )
	  	
	COUNTY OF	  	)	  	

 On this          day of September, 2013, before me, the undersigned notary public,
personally appeared                     
                    , known personally to me, or proved to me through satisfactory evidence of identification, which was
                        
                    , to be the person whose name is signed on the preceding or attached document, and acknowledged to me that he signed it
voluntarily for its stated purpose, as the duly authorized signatory of the above entities, and signed the foregoing instrument for the purposes therein contained as his/her free act and deed. 

 

	
	 
	My commission expires

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 23

 CONFIDENTIAL 

 

 EXHIBIT A 

TO AMENDED AND RESTATED NOTICE OF LEASE 

Legal Description of the Property 
 The land,
with the improvements to be constructed thereon, shown as Lot 2 on a plan entitled “Consolidation and Subdivision Plan 75 Binney Street, 125 Binney Street and proposed 270 Third Street Cambridge, Mass.” Dated October 9,
2012, prepared by Harry R. Feldman, Inc., recorded with the Suffolk Registry of Deeds as Plan No. 795 of 2012. 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

			
	First Amendment To Lease – ARIAD Pharmaceuticals	  	 Page 
 24

 CONFIDENTIAL 

 

 EXHIBIT A-1 

TO AMENDED AND RESTATED NOTICE OF LEASE 

Plan of Expansion Space and Plan of New Atrium Area 

[See Exhibit A to the Lease] 

  
 © All Rights
Reserved 2001 Alexandria Real Estate Equities, Inc. 
 CONFIDENTIAL – DO NOT COPY 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.EX-4.01

 Exhibit 4.01 

This Note is a Global Security within the meaning of the Indenture hereinafter referred to and is registered in the name of the Depository
named below or a nominee of the Depository. This Note is not exchangeable for Notes registered in the name of a Person other than the Depository or its nominee except in the limited circumstances described herein and in the Indenture, and no
transfer of this Note (other than a transfer of this Note as a whole by the Depository to a nominee of the Depository or by a nominee of the Depository to the Depository or another nominee of the Depository) may be registered except in the limited
circumstances described herein. 
 Unless this certificate is presented by an authorized representative of The Depository Trust Company, a
New York corporation (the “Depository”), to the Company or its agent for registration of transfer, exchange, or payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as is requested by
an authorized representative of the Depository (and any payment is made to Cede & Co. or to such other entity as is requested by an authorized representative of the Depository), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR
OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest herein. 

CITIGROUP INC. 
 Floating
Rate Notes due November 9, 2018 
  

					
	REGISTERED	  		  	REGISTERED
			
		  		  	CUSIP: 172967 HF 1
		  		  	ISIN: US172967HF12
		  		  	Common Code: 099433060
			
	No. R-0001	  		  	$500,000,000

 CITIGROUP INC., a Delaware corporation (the “Company”, which term includes any successor Person
under the Indenture), for value received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum of $500,000,000 on November 9, 2018 and to pay interest thereon from and including November 12, 2013 or from
the most recent Interest Payment Date to which interest has been paid or duly provided for, quarterly, on the ninth day of each February, May, August and November, commencing February 9, 2014, at the rate per annum for each Interest Period of
three-month LIBOR, determined as provided herein, plus 0.880% until the principal hereof is paid or made available for payment. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the
Indenture, be paid to the Person in whose name this Note is registered at the close of business on the Record Date for such interest, which shall be the Business Day immediately preceding such Interest Payment Date. 

Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the holder on such Record Date and may
either be paid to the Person in whose name this Note is registered at the close of business on a subsequent Record Date, such subsequent Record Date to be not less than five days prior to the date of payment of such defaulted interest, notice
whereof shall be given to holders of Notes of this series not less than 15 days prior to such subsequent Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the
Notes of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture. 

 Interest hereon will be calculated on the basis of the actual number of days elapsed in an
Interest Period and a 360-day year. Dollar amounts resulting from such calculation will be rounded to the nearest cent, with one-half cent being rounded upward. An “Interest Period” shall be the period from and including an Interest
Payment Date (or from November 12, 2013 in the case of the first Interest Payment Date) to and including the day immediately preceding the next Interest Payment Date. 

If an Interest Payment Date falls on a day that is not a Business Day, such Interest Payment Date will be the next succeeding Business Day. If
the Maturity of the Notes falls on a day that is not a Business Day, the payment due on Maturity will be postponed to the next succeeding Business Day, and no further interest will accrue in respect of such postponement. If a date for payment of
interest or principal on the Notes falls on a day that is not a business day in the place of payment, such payment will be made on the next succeeding business day in such place of payment as if made on the date the payment was due. No interest will
accrue on any amounts payable for the period from and after the due date for payment of such principal or interest. 
 For these purposes,
“Business Day” means any day which is a day on which commercial banks settle payments and are open for general business in The City of New York. 

Payment of the principal of and interest on this Note will be made at the office or agency of the Trustee maintained for that purpose in The
City of New York. 
 Reference is hereby made to the further provisions of this Note set forth on the reverse hereof, which further
provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of authentication hereon has
been executed by the Trustee or by an authenticating agent on behalf of the Trustee by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 2 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
 Dated: November 12, 2013 
  

							
		 	CITIGROUP INC.
				
		 	By:	  	  
	  	
		 	Title:	  	Deputy Treasurer	  	

  

			
	ATTEST:
		
	By:	 	  

	Title:	 	Assistant Secretary

  
 3 

 This is one of the Notes of the series issued under the within-mentioned Indenture. 

Dated: November 12, 2013 
  

							
		 	THE BANK OF NEW YORK MELLON,
		 	as Trustee
				
		 	By:	  	  
	  	
		 		  	Name:	  	
		 		  	Title:	  	
				
		 	-or-	  		  	
		
		 	 CITIBANK, N.A.,
 as Authenticating
Agent

				
		 	By:	  	  
	  	
		 		  	Name:	  	
		 		  	Title:	  	

  
 4 

 This Note is one of a duly authorized issue of Securities of the Company (the “Notes”),
issued and to be issued in one or more series under the Indenture, dated as of March 15, 1987 (as amended and supplemented to date, the “Indenture”), between the Company and The Bank of New York Mellon, formerly known as The Bank of
New York, as Trustee (the “Trustee”, which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations
of rights, duties and immunities thereunder of the Company, the Trustee and the holders of the Notes and of the terms upon which the Notes are, and are to be, authenticated and delivered. This Note is one of the series designated on the face hereof,
limited in aggregate principal to $500,000,000. 
 This Note will bear interest for each Interest Period at a rate determined by Citibank,
N.A., acting as Calculation Agent. The interest rate on this Note for a particular Interest Period will be a per annum rate equal to three-month LIBOR as determined on the related Interest Determination Date, plus 0.880%. The Interest Determination
Date for an Interest Period will be the second London business day preceding such Interest Period. The Interest Determination Date for the first Interest Period was November 8, 2013. Promptly upon determination, the Calculation Agent will
inform the Trustee and the Company of the interest rate for the next Interest Period. Absent manifest error, the determination of the interest rate by the Calculation Agent shall be binding and conclusive on the holders of Notes, the Trustee and the
Company. 
 A London business day is a day on which dealings in deposits in U.S. dollars are transacted in the London interbank market. 

On any Interest Determination Date, LIBOR will be equal to the offered rate for deposits in U.S. dollars having an index maturity of three
months for the next Interest Period, in amounts of at least $1,000,000, as such rate appears on Reuters Screen LIBOR01 at approximately 11:00 a.m., London time, on such Interest Determination Date. If the Reuters Screen LIBOR01 is replaced by
another service or ceases to exist, the Calculation Agent will use the replacing service or such other service that may be nominated by the British Bankers’ Association for the purpose of displaying London interbank offered rates for U.S.
dollar deposits. 
 If no offered rate appears on Reuters Screen LIBOR01 on an Interest Determination Date at approximately 11:00 a.m.,
London time, then the Calculation Agent (after consultation with the Company) will select four major banks in the London interbank market and shall request each of their principal London offices to provide a quotation of the rate at which
three-month deposits in U.S. dollars in amounts of at least $1,000,000 are offered by it to prime banks in the London interbank market, on that date and at that time, that is representative of single transactions at that time. If at least two
quotations are provided, LIBOR will be the arithmetic average of the quotations provided. Otherwise, the Calculation Agent will select three major banks in New York City and shall request each of them to provide a quotation of the rate offered by
them at approximately 11:00 a.m., New York City time, on the Interest Determination Date for loans in U.S. dollars to leading European banks having an index maturity of three months for the applicable Interest Period in an amount of at least
$1,000,000 that is representative of single transactions at that time. If three quotations are provided, LIBOR will be the arithmetic average of the quotations provided. Otherwise, the rate of LIBOR for the next Interest Period will be set equal to
the rate of LIBOR for the current Interest Period. 

  
 5 

 The Luxembourg Stock Exchange shall be notified of the interest rate, the amount of the interest
payment and the Interest Payment Date for a particular Interest Period not later than the first day of such Interest Period. Upon request from any Noteholder, the Calculation Agent will provide the interest rate in effect on this Note for the
current Interest Period and, if it has been determined, the interest rate to be in effect for the next Interest Period. 
 If an event of
default (as defined in the Indenture) with respect to Notes of this series shall occur and be continuing, the principal of the Notes of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 

The Indenture contains provisions for defeasance at any time of the entire indebtedness of this Note upon compliance by the Company with
certain conditions set forth in Sections 11.03 and 11.04 thereof, which provisions apply to this Note. 
 The Indenture contains provisions
permitting the Company and the Trustee, without the consent of the holders of the Securities, to establish, among other things, the form and terms of any series of Securities issuable thereunder by one or more supplemental indentures, and, with the
consent of the holders of not less than 66 2/3% in aggregate principal amount of Securities at the time outstanding which are affected thereby, to modify the Indenture or any supplemental indenture or the rights of the holders of Securities of such
series to be affected, provided that no such modification will (i) extend the fixed maturity of any Securities, reduce the rate or extend the time of payment of interest thereon, reduce the principal amount thereof or the premium, if any,
thereon, reduce the amount of the principal of Original Issue Discount Securities payable on any date, change the currency in which Securities are payable, or impair the right to institute suit for the enforcement of any such payment on or after the
maturity thereof, without the consent of the holder of each Security so affected, or (ii) reduce the aforesaid percentage of Securities of any series the consent of the holders of which is required for any such modification without the consent
of the holders of all Securities of such series then outstanding, or (iii) modify, without the written consent of the Trustee, the rights, duties or immunities of the Trustee. 

No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Company,
which is absolute and unconditional, to pay the principal of and interest on this Note at the times, place and rate, and in the coin or currency, herein prescribed. 

This Note is a Global Security registered in the name of a nominee of the Depository. This Note is exchangeable for Notes registered in the
name of a person other than the Depository or its nominee only in the limited circumstances hereinafter described. Unless and until it is exchanged in whole or in part for definitive Notes in certificated form, this Note may not be transferred
except as a whole by the Depository to a nominee of the Depository or by a nominee of the Depository to the Depository or another nominee of the Depository. 

  
 6 

 The Notes represented by this Global Security are exchangeable for definitive Notes in
certificated form of like tenor as such Notes in denominations of $1,000 and whole multiples of $1,000 in excess thereof only if (i) the Depository notifies the Company that it is unwilling or unable to continue as Depository for the Notes or
(ii) the Depository ceases to be a clearing agency registered under the Securities Exchange Act of 1934, as amended, or (iii) the Company in its sole discretion decides to allow the Notes to be exchanged for definitive Notes in registered
form. Any Notes that are exchangeable pursuant to the preceding sentence are exchangeable for certificated Notes issuable in authorized denominations and registered in such names as the Depository shall direct. As provided in the Indenture and
subject to certain limitations therein set forth, the transfer of definitive Notes in certificated form is registrable in the register maintained by the Company in The City of New York for such purpose, upon surrender of the definitive Note for
registration of transfer at the office or agency of the registrar, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the registrar duly executed by, the holder thereof or his attorney duly
authorized in writing, and thereupon one or more new Notes of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. Subject to the
foregoing, this Note is not exchangeable, except for a Global Security or Global Securities of this issue of the same principal amount to be registered in the name of the Depository or its nominee. 

No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to
cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Note for registration of
transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Note is registered as the owner hereof for all purposes, whether or not this Note be overdue, and neither the Company, the Trustee
nor any such agent shall be affected by notice to the contrary. 
 The Company will pay additional amounts (“Additional Amounts”)
to the beneficial owner of any Note that is a non-United States person in order to ensure that every net payment on such Note will not be less, due to payment of U.S. withholding tax, than the amount then due
and payable. For this purpose, a “net payment” on a Note means a payment by the Company or a paying agent, including payment of principal and interest, after deduction for any present or future tax, assessment or other governmental charge
of the United States. These Additional Amounts will constitute additional interest on the Note. 
 The Company will not be required to pay
Additional Amounts, however, in any of the circumstances described in items (1) through (14) below. 
  

	 	(1)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely by reason of the beneficial owner:

  

	 	(a)	having a relationship with the United States as a citizen, resident or otherwise; 

  
 7 

	 	(b)	having had such a relationship in the past or 

  

	 	(c)	being considered as having had such a relationship. 

  

	 	(2)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely by reason of the beneficial owner:

  

	 	(a)	being treated as present in or engaged in a trade or business in the United States; 

  

	 	(b)	being treated as having been present in or engaged in a trade or business in the United States in the past or 

  

	 	(c)	having or having had a permanent establishment in the United States. 

  

	 	(3)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld in whole or in part by reason of the beneficial owner
being or having been any of the following (as such terms are defined in the Internal Revenue Code of 1986, as amended): 

  

	 	(a)	personal holding company; 

  

	 	(b)	foreign personal holding company; 

  

	 	(c)	foreign private foundation or other foreign tax-exempt organization; 

  

	 	(d)	passive foreign investment company; 

  

	 	(e)	controlled foreign corporation or 

  

	 	(f)	corporation which has accumulated earnings to avoid United States federal income tax. 

  

	 	(4)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely by reason of the beneficial owner owning or
having owned, actually or constructively, 10 percent or more of the total combined voting power of all classes of stock of the Company entitled to vote or by reason of the beneficial owner being a bank that has invested in a Note as an extension of
credit in the ordinary course of its trade or business. 

 For purposes of items (1) through (4) above, “beneficial owner”
means a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder is an estate, trust, partnership, limited liability company, corporation or other entity, or a person holding a power over an estate or trust administered by
a fiduciary holder. 
  

	 	(5)	Additional Amounts will not be payable to any beneficial owner of a Note that is a: 

  

	 	(a)	fiduciary; 

  

	 	(b)	partnership; 

  

	 	(c)	limited liability company or 

  

	 	(d)	other fiscally transparent entity 

  
 8 

 or that is not the sole beneficial owner of the Note, or any portion of the Note. However, this
exception to the obligation to pay Additional Amounts will only apply to the extent that a beneficiary or settlor in relation to the fiduciary, or a beneficial owner or member of the partnership, limited liability company or other fiscally
transparent entity, would not have been entitled to the payment of an Additional Amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment. 

 

	 	(6)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely by reason of the failure of the beneficial
owner or any other person to comply with applicable certification, identification, documentation or other information reporting requirements. This exception to the obligation to pay Additional Amounts will only apply if compliance with such
reporting requirements is required by statute or regulation of the United States or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge.

  

	 	(7)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is collected or imposed by any method other than by withholding from a
payment on a Note by the Company or a paying agent. 

  

	 	(8)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld by reason of a change in law, regulation, or
administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later. 

  

	 	(9)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld by reason of the presentation by the beneficial owner
of a Note for payment more than 30 days after the date on which such payment becomes due or is duly provided for, whichever occurs later. 

  

	 	(10)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any: 

  

	 	(a)	estate tax; 

  

	 	(b)	inheritance tax; 

  

	 	(c)	gift tax; 

  

	 	(d)	sales tax; 

  

	 	(e)	excise tax; 

  

	 	(f)	transfer tax; 

  

	 	(g)	wealth tax; 

  
 9 

	 	(h)	personal property tax or 

  

	 	(i)	any similar tax, assessment, withholding, deduction or other governmental charge. 

  

	 	(11)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment, or other governmental charge required to be withheld by any paying agent from a payment of principal or
interest on a Note if such payment can be made without such withholding by any other paying agent. 

  

	 	(12)	Additional amounts will not be payable if a payment on a Note is reduced as a result of any tax, assessment or other governmental charge that is required to be made pursuant to any European Union directive on the
taxation of savings income or any law implementing or complying with, or introduced to conform to, any such directive. 

  

	 	(13)	Additional amounts will not be payable if a payment on a Note is reduced as a result of any withholding, deduction, tax, duty assessment or other governmental charge that would not have been imposed but for a failure by
the holder or beneficial owner of a Note (or any financial institution through which the holder or beneficial owner holds the Note or through which payment on the Note is made) to take any action (including entering into an agreement with the
Internal Revenue Service, or a governmental authority of another jurisdiction if the holder is entitled to the benefits of an intergovernmental agreement between that jurisdiction and the United States) or to comply with any applicable
certification, documentation, information or other reporting requirement or agreement concerning accounts maintained by the holder or beneficial owner (or any such financial institution), or concerning ownership of the holder or beneficial owner, or
any substantially similar requirement or agreement. 

  

	 	(14)	Additional Amounts will not be payable if a payment on a Note is reduced as a result of any combination of items (1) through (13) above. 

Except as specifically provided herein, the Company will not be required to make any payment of any tax, assessment or other governmental
charge imposed by any government or a political subdivision or taxing authority of such government. 
 As used in this Note, “United
States person” means: 
  

	 	(a)	any individual who is a citizen or resident of the United States; 

  

	 	(b)	any corporation, partnership or other entity created or organized in or under the laws of the United States; 

  

	 	(c)	any estate if the income of such estate falls within the federal income tax jurisdiction of the United States regardless of the source of such income and 

 

	 	(d)	any trust if a United States court is able to exercise primary supervision over its administration and one or more United States persons have the authority to control all of the substantial decisions of the trust.

  
 10 

 Additionally, “non-United States person” means
a person who is not a United States person, and “United States” means the states of the United States of America and the District of Columbia, but excluding its territories and its possessions. 

Except as provided below, the Notes may not be redeemed prior to maturity. 

 

	 	(1)	The Company may, at its option, redeem the Notes if: 

  

	 	(a)	the Company becomes or will become obligated to pay Additional Amounts as described above; 

  

	 	(b)	the obligation to pay Additional Amounts arises as a result of any change in the laws, regulations or rulings of the United States, or an official position regarding the application or interpretation of such laws,
regulations or rulings, which change is announced or becomes effective on or after November 6, 2013 and 

  

	 	(c)	the Company determines, in its business judgment, that the obligation to pay such Additional Amounts cannot be avoided by the use of reasonable measures available to it, other than substituting the obligor under the
Notes or taking any action that would entail a material cost to the Company. 

  

	 	(2)	The Company may also redeem the Notes, at its option, if: 

  

	 	(a)	any act is taken by a taxing authority of the United States on or after November 6 2013, whether or not such act is taken in relation to the Company or any affiliate, that results in a substantial probability that
the Company will or may be required to pay Additional Amounts as described above; 

  

	 	(b)	the Company determines, in its business judgment, that the obligation to pay such Additional Amounts cannot be avoided by the use of reasonable measures available to it, other than substituting the obligor under the
Notes or taking any action that would entail a material cost to the Company and 

  

	 	(c)	the Company receives an opinion of independent counsel to the effect that an act taken by a taxing authority of the United States results in a substantial probability that the Company will or may be required to pay the
Additional Amounts described above, and delivers to the Trustee a certificate, signed by a duly authorized officer, stating that based on such opinion the Company is entitled to redeem the Notes pursuant to their terms. 

Any redemption of the Notes as set forth in clauses (1) or (2) above shall be in whole, and not in part, and will be made at a redemption price
equal to 100% of the principal amount of the Notes Outstanding plus accrued interest thereon to the date of redemption. Holders shall be given not less than 30 days’ nor more than 60 days’ prior notice by the Trustee of the date fixed for
such redemption. 

  
 11 

 All terms used in this Note which are defined in the Indenture shall have the meanings assigned
to them in the Indenture. The Notes are governed by the laws of the State of New York. 

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]